Birgit V.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Evaluation of Image-Guided De-Escalation of Neoadjuvant Chemotherapy with Trastuzumab, Pertuzumab, and Drug Combination in HER2-Positive Breast Cancer
- Evaluation of CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib in HR+/HER2- Metastatic Breast Cancer: A Randomized Clinical Trial
Data & Insights
Has run more than one trial at 64 of 268 partner sites.
Specializations
Breast Cancer Therapeutics
This investigator specializes in developing innovative treatments for HER2-positive breast cancer, with particular emphasis on exploring neoadjuvant chemotherapy approaches and image-guided treatment optimization.
- HER2-targeted therapies
- Dual HER2-blockade strategies
- Treatment de-escalation protocols
Their work extends to evaluating therapeutic responses through advanced imaging techniques.
Hormone Receptor-Positive Disease
The investigator focuses on advancing treatment options for hormone receptor-positive breast cancer, particularly investigating novel endocrine therapies and targeted combinations.
- CDK4/6 inhibition strategies
- Endocrine therapy sequencing
- Novel therapeutic agents
Their research encompasses both early-stage and metastatic disease settings.
Triple Negative Breast Cancer
The investigator conducts research in triple negative breast cancer treatment, focusing on biomarker-driven approaches and innovative combination therapies.
- Platinum-based treatments
- Immunotherapy combinations
- Biomarker validation studies
Their work includes first-line treatment strategies and predictive testing methodologies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.